Abstract
Neuroimaging, both structural and functional, serve as useful adjuncts to clinical assessment, and can provide objective, reliable means of assessing disease presence and process in the aging population. In the following review we briefly explain current imaging methodologies. Then, we analyze recent developments in developing neuroimaging biomarkers for two highly prevalent disorders in the elderly population- Alzheimer's disease (AD) and late-life depression (LLD). In AD, efforts are focused on early diagnosis through in vivo visualization of disease pathophysiology. In LLD, recent imaging evidence supports the role of white matter ischemic changes in the pathogenesis of depression in the elderly, the "vascular hypothesis." Finally, we discuss potential roles for neuroimaging biomarkers in geriatric psychiatry in the future.
Original language | English (US) |
---|---|
Article number | 360 |
Journal | Current psychiatry reports |
Volume | 15 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2013 |
Externally published | Yes |
Keywords
- Alzheimer's disease (AD)
- Biomarkers
- DTI
- Dementia
- FDG-PET
- Geriatric
- Late-life depression (LLD)
- MRI
- Neuroimaging
- PET
- Pittsburgh Compound B (PiB)
- Psychiatry
- Resting-state network
- Vascular hypothesis
- White matter lesions (WML)
- fMRI
ASJC Scopus subject areas
- Psychiatry and Mental health